Jakarta (ANTARA) - The Brawijaya University in Malang, East Java, has developed an initial screening kit for diabetes mellitus and is preparing for its commercialization in Indonesia and overseas.
Developed by a research team led by Prof. Dr. Aulanni'am, drh., DES., the biosciences rapid test GAD65 can be used for early screening of diabetes, before preventive measures and course of treatment are determined.
The reverse-flow immunochromatography-based detection kit identifies the presence of autoantibodies against GAD65, which indicate damage to beta-pancreatic cells, a marker for Type 1 Diabetes Mellitus and Latent Autoimmune Diabetes in Adults (LADA).
Diabetes is a global health threat that often leads to several complications that can have an impact on the quality of human resources as well as substantially add to health costs of families and countries.
The increasing prevalence of diabetes has raised concerns globally and prompted prevention efforts. Detecting and managing the condition through appropriate therapy has been shown to be crucial for preventing any deterioration in the condition of people suffering from the metabolic disease.
The bioscience rapid test GAD65 is among the downstream products developed as part of the cooperation between Brawijaya University and state-owned pharmaceutical company PT Bio Farma (Persero).
The preparation and production of the kit has involved various levels of research and testing, based on the consensus and regulations set by the World Health Organization (WHO) and the Indonesian Health Ministry.
The screening kit, which has a medical device distribution permit and meets the certification requirements for good medical device manufacturing from the health ministry, is currently ready to be produced and distributed widely.
The detection kit has also been introduced to potential international consumers in Spain, Taiwan, Japan, Saudi Arabia, Jordan, Madagascar, the Philippines, and Malaysia.
As part of the collaboration for the downstreaming process of the kit, Brawijaya University has been designated as the producer and PT Bio Farma as the main distributor of the patented product (ID. 0.022.556 B, 2009-Granted and P00201910578, 2019-Registered). (INE)
